This product is suitable for research use only. There are a number of products that are identified as 'generic' compounds, including those with the SML prefix. However, none of these compounds would be suitable for use as Active Pharmaceutical Ingredients. Unfortunately, these products have not been listed in a single brochure.
SML2014
Deracoxib
≥98% (HPLC)
Synonyme(s) :
4-[3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(3-Fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-046, SC-46, SC-59046
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
| À vous/Référence | Disponibilité | Prix |
|---|
A propos de cet article
Formule empirique (notation de Hill) :
C17H14F3N3O3S
Numéro CAS:
Poids moléculaire :
397.37
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Le tarif et la disponibilité ne sont pas disponibles actuellement.
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderassay
≥98% (HPLC)
form
powder
color
white to brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
room temp
SMILES string
FC(F)c1n[n](c(c1)c3cc(c(cc3)OC)F)c2ccc(cc2)[S](=O)(=O)N
InChI
1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)
InChI key
WAZQAZKAZLXFMK-UHFFFAOYSA-N
Biochem/physiol Actions
Deracoxib is an orally active cyclooxygenase-2 (COX-2) inhibitor with >48-fold selectivity over COX-1 (IC50 of 203-189 nM against COX-2-dependent PGE2 production vs. IC50 of 9.85-9.96 μM against COX-1-dependent TxB2 production in dog whole blood). Deracoxib is also reported to exhibit inhibitory activity against phosphodiesterase (Ki = 3.6 μM against human PDE4D3) as well as positive modulatory effiacy toward 2-APB-stimulated transient receptor potential vanilloid 3 channel (TRPV3) activity.
Orally active COX-2 inhibitor with >48-fold selectivity over COX-1. Also inhibits PDE4D3 and enhances 2-APB-stimulated TRPV3 activity.
1 of 1
Cet article | |||
|---|---|---|---|
| description ≥98% (HPLC) | description ≥98% (HPLC) | description ≥98% (HPLC) | description ≥98% (HPLC) |
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| storage temp. room temp | storage temp. room temp | storage temp. -10 to -25°C | storage temp. 2-8°C |
| solubility DMSO: 2 mg/mL, clear | solubility DMSO: 20 mg/mL, clear | solubility DMSO: 2 mg/mL, clear | solubility DMSO: 20 mg/mL, clear |
| color white to brown | color white to beige | color white to beige | color white to beige |
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
-
SML- portfolio recommended for which segments? Can we offer this to customer as INNs (International Nonproprietary Names) standards. Please also share with us the complete brochure of SML- products.
1 réponse-
Utile ?
-